Clinical trials: Chemoradiotherapy
Esophageal Cancer, Concurrent Chemoradiotherapy
CCRT for Esophageal Cancer.
This study aimed at assessing the efficiency and safety of concurrent chemoradiotherapy (CCRT) using paclitaxel (PTX) plus oxaliplatin (OHP) in unresectable locally advanced esophageal cancer patients.
- Conditions
- Esophageal Cancer, Concurrent Chemoradiotherapy, Oxaliplatin, Paclitaxel
- Trial name
- NCT02607982
- Testing
- Paclitaxel, Oxaliplatin, Radiotherapy
- Volunteers
- 34 people
- Sponsor
- Hangzhou Cancer Hospital
Pancreatic Cancer
Gemcitabine, Cisplatin, and Radiation Therapy Followed By Surgery or Surgery Alone in Treating Patients With Localized Pancreatic Cancer That Can Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00335543
- Testing
- cisplatin, gemcitabine hydrochloride, adjuvant therapy
- Where
- 17 sites in Austria, Germany and 1 more
- Volunteers
- 254 people
- Sponsor
- Interdisziplinare Arbeitsgruppe Gastrointestinaler Tumore der Deutschen Krebsgesellschaft
Brain Cancer, Head and Neck Cancer
A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients
The purpose of this study is to determine the safety of Velcade when used with chemoradiation in cancer patients.
- Conditions
- Brain Cancer, Head and Neck Cancer, Cervix Cancer, Central Nervous System Neoplasms
- Trial name
- NCT00329589
- Testing
- Velcade (bortezomib)
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Non-Small-Cell-Lung Cancer
Evaluation of Carboplatin Plus Gemcitabine Followed by Concomitant Chemoradiation for Non-resectable Stage III NSCLC
The aim of this study is to evaluate whether by combining a carboplatin-gemcitabine based induction chemotherapy with weekly cisplatin during standard thoracic radiotherapy it is possible to obtain optimal efficacy with minimal…
- Trial name
- CHER@NOS (NCT00463515)
- Testing
- carboplatin/gemcitabine, cisplatin/radiation therapy
- Where
- 3 sites in Belgium
- Volunteers
- 77 people
- Sponsor
- University Hospital, Antwerp
Locally Advanced Rectal Cancer
Total Neoadjuvant Therapy Combined With Tislelizumab for Local Advanced of Middle and Low Rectal Cancer
This study is a prospective, randomized, open, controlled, multi-center phase II clinical trial, which included patients with locally advanced low rectal cancer as the research object, and evaluated the application of long-term…
- Trial name
- NCT05845268
- Testing
- Long-course chemoradiation, with Tislelizumab (PD-1 inhibitor), Long-course chemoradiation, without Tislelizumab (PD-1 inhibitor)
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Beijing Friendship Hospital
Esophageal Cancer
S-1, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIA, Stage III, or Stage IVA Esophageal Cancer That Can Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as S-1 and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00659113
- Testing
- cisplatin, tegafur-gimeracil-oteracil potassium, cytology specimen collection procedure
- Where
- South Korea
- Volunteers
- 32 people
- Sponsor
- Yonsei University
Rectal Cancer
Optimisation of Response for Organ Preservation in Rectal Cancer : Neoadjuvant Chemotherapy and Radiochemotherapy vs. Radiochemotherapy
Standard treatment of rectal cancer is rectal excision with neoadjuvant radiochemotherapy. A new concept suggests organ preservation as an alternative to rectal excision in good responders after neoadjuvant radiochemotherapy to…
- Trial name
- GRECCAR12 (NCT02514278)
- Testing
- Neoadjuvant chemotherapy Folfirinox, 4 cycles, 50 Gy, 2 Gy/session; 25 fractions, Local excision in good responders
- Where
- 29 sites in France
- Volunteers
- 218 people
- Sponsor
- University Hospital, Bordeaux
Glioma
Study on Radiogenomics Features Associated With Radiochemotherapy Sensitivity in Gliomas
The MRI data were collected from patients with gliomas before surgery, 2 weeks before initiating radiochemotherapy, 1 month after completing the radiotherapy (for lower-grade gliomas, LGG), or 4 and 10 months after completing the…
- Trial name
- NCT06454097
- Testing
- Assess the response glioma to radiochemotherapy using radiogenomics-based AI model
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Beijing Tiantan Hospital
Colon Cancer
Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color）
The goal of this clinical trial is to evaluate the efficacy and safety of conversion therapy using radiotherapy combined with systemic treatment (chemotherapy + immune checkpoint inhibitors) for patients with pMMR/MSS T4M0 stage…
- Trial name
- NCT06949111
- Testing
- radiotherapy, CAPOX, Capecitabine
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Hebei Medical University Fourth Hospital
Esophageal Cancer, Gastroesophageal Cancer
Oxaliplatin-Based Chemotherapy and Chemoradiotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Carcinoma
The goal of this clinical research study is to learn if a combination of the investigational drug oxaliplatin with 5-Fluorouracil (5-FU) (given at the same time as radiation therapy) is as effective as a combination of these two…
- Trial name
- NCT00525915
- Testing
- 5-Fluorouracil, Oxaliplatin, Radiation Therapy
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- M.D. Anderson Cancer Center
Cervical Cancer
The Efficacy of Salvage Surgery in Patients With Residual Tumor After Concurrent Chemoradiation for Locally Advanced Cervical Cancer.
This is a single-center single-arm study. The main purpose of this study is to study the efficacy of surgical treatment for patients with locally advanced cervical cancer (FIGO IB3, IIA2-IVA) who still have residual tumor after…
- Trial name
- NCT05749887
- Testing
- salvage surgery
- Where
- China
- Volunteers
- 188 people
- Sponsor
- Chongqing University Cancer Hospital
Oropharyngeal Cancer
Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer
This is a single-center phase 2 study of to test how well the combination of toripalimab with chemotherapy followed by TORS or risk and response stratified de-escalated (chemo)radiotherapy works in patients with in HPV16+…
- Trial name
- NCT07290621
- Testing
- Toripalimab, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Chicago
Esophageal Adenocarcinoma
Propranolol With Chemotherapy or Chemoradiation for Esophageal Adenocarcinoma
This phase II trial studies the side effects and best dose of propranolol when administered concurrently with SOC neoadjuvant CRT in patients with esophageal carcinoma, with a safety lead-in and dose expansion cohort.
- Trial name
- NCT04682158
- Testing
- Carboplatin, 3 Dimensional Conformal Radiation Therapy, Propranolol
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- Roswell Park Cancer Institute
Head and Neck Cancer
Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck
Primary Compare response rates (relative change in tumor size) to induction chemotherapy consisting of cisplatin/paclitaxel/cetuximab +/- everolimus.
- Trial name
- NCT01133678
- Testing
- Everolimus
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Chicago
Esophagus Adenocarcinoma
Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery
The present clinical trial is a prospective, investigator-initiated, single-arm, open-label, multicenter phase II trial investigating whether a definite organ preservation therapy consisting of the combination of durvalumab with…
- Trial name
- NCT05713838
- Testing
- Durvalumab, FLOT, mFOLFOX-6
- Where
- 22 sites in Germany
- Volunteers
- 32 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Squamous Cell Carcinoma, Adenocarcinoma
Chemoradiation and Panitumumab for Esophageal Cancer
A consistent finding in many studies in patients with operable esophageal and gastro-esophageal junction (GEJ) cancer is that response to preoperative therapy, particularly the absence of residual disease in the surgical…
- Conditions
- Squamous Cell Carcinoma, Adenocarcinoma, Esophageal Cancer, Gastro-esophageal Junction Cancer
- Trial name
- NCT01077999
- Testing
- Carboplatin, Paclitaxel, panitumumab
- Where
- Netherlands
- Volunteers
- 78 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Esophageal Squamous Cell Carcinoma
TPF Concurrent Chemo-radiotherapy Plus Immunotherapy for Local Advanced Esophageal Squamous Cell Carcinoma
The goal of this clinical trial is to learn if immune microenvironment modification could improve the effect of chemoradiotherapy for patients with local advanced esophageal squamous cell carcinoma.
- Trial name
- NCT06401447
- Testing
- Radiotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fudan University
Nasopharyngeal Carcinoma
Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma
This is an open, multicenter phase Ⅱ clinical trial. The purpose of this study is to evaluate acute toxicity and efficacy of cetuximab (C225) combined with IMRT + neoadjuvant chemotherapy in advanced T stage of nasopharyngeal…
- Trial name
- REPLACE (NCT01271439)
- Testing
- Cetuximab
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Malignant Glioma
Mindfulness Meditation in Glioma Patients
This pilot study is designed to determine the feasibility of providing a mindfulness meditation program to patients with newly diagnosed malignant glioma during standard of care chemoradiation.
- Trial name
- NCT03915912
- Testing
- Mindfulness meditation
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Duke University
Esophageal Squamous Cell Carcinoma
AK104 Plus Concurrent Chemoradiation Therapy in Esophageal Squamous Cell Carcinoma
The purpose of this study is to assess the safety and efficacy of AK104 plus concurrent chemoradiation therapy in unresectable locally advanced esophageal squamous cell carcinoma
- Trial name
- NCT05594914
- Testing
- AK104
- Volunteers
- 47 people
- Sponsor
- The First Affiliated Hospital of University of South China
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.